Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07082829 · ClinicalTrials.gov registry record · Phase 1
A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
A Phase 1 study of Excessive Daytime Sleepiness, sponsored by Centessa Pharmaceuticals (UK) Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 208
- Enrollment target
- 3
- Study locations
NCT07082829: Recruiting Phase 1 study of Excessive Daytime Sleepiness, sponsored by Centessa Pharmaceuticals (UK) Limited.
NCT07082829 is a Phase 1 study of Excessive Daytime Sleepiness that is actively recruiting participants, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 208 participants, above the 112-participant average among 3 other Excessive Daytime Sleepiness trials with a reported enrollment target (86% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07082829, a Phase 1 study of Excessive Daytime Sleepiness, is actively recruiting participants, sponsored by Centessa Pharmaceuticals (UK) Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 208 participants
- Enrollment target
- 3
- Study locations
Study Summary
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Primary Outcome
Safety and Tolerability as assessed by AEs and SAEs
Conditions Studied
Interventions
- OTHER Placebo Tablets
- DRUG ORX142 Tablets
Study Locations (3)
Nebraska
- Site #1 - Lincoln
New Jersey
- Site #2 - Eatontown
New York
- Site #3 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2025-06-30 |
| Est. Completion | 2026-06-15 |
| Phase | Phase 1 |
What NCT07082829 shows while recruiting
NCT07082829 is an interventional study that assigns participants to a tested intervention. The registered 208 participants enrollment target is mid-sized for trials with a published cap, above the 112-participant average among 3 other Excessive Daytime Sleepiness trials with a reported enrollment target (86% higher).
The record links to 1 condition, with Excessive Daytime Sleepiness appearing as the primary indexed condition, and to 2 interventions - of which Placebo Tablets is the first listed.
NCT07082829 reports a single indexed study location in Nebraska, New Jersey, New York.
Frequently Asked Questions
What is clinical trial NCT07082829 about?
NCT07082829 is a clinical study titled "A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age". Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
What is the current status of trial NCT07082829?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 208 participants. The study started on 2025-06-30. Estimated completion is 2026-06-15.
What conditions does trial NCT07082829 study?
This clinical trial studies the following conditions: Excessive Daytime Sleepiness.
What interventions are being tested in trial NCT07082829?
The interventions under investigation include: Placebo Tablets (OTHER), ORX142 Tablets (DRUG).
Who is sponsoring clinical trial NCT07082829?
This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07082829 being conducted?
This trial has 3 study locations across Nebraska, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Excessive Daytime Sleepiness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Bright Light Therapy on Prader-Willi Syndrome
RECRUITING · NA
-
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
COMPLETED · Phase 4
-
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465774 · 208 participants
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
- NCT03803332 · 208 participants · NA
A Trial Comparing Interpersonal Therapy to Exposure Therapy for PTSD Due to Military Sexual Trauma (MST) in Male and Female Military Personnel
- NCT04732065 · 208 participants · Phase 1
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
- NCT05293756 · 208 participants · NA
OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI